CHRISTOPHER SUPERCZYNSKI: Open Payments
NPI 1184621138 · LINCOLN, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,101 in 101 payments from 19 companies in 2025. Trend: 2023 $1,708 · 2024 $1,779 · 2025 $2,101
Food & beverage: $2,101
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 18 | $358 |
| ABBVIE INC. | 18 | $310 |
| AstraZeneca Pharmaceuticals LP | 10 | $289 |
| Abbott Laboratories | 9 | $178 |
| GlaxoSmithKline, LLC. | 6 | $114 |
| Novo Nordisk Inc | 4 | $104 |
| Lundbeck LLC | 5 | $102 |
| Sumitomo Pharma America, Inc. | 4 | $88 |
| TOLMAR, INC. | 3 | $87 |
| Exact Sciences Corporation | 5 | $83 |
Products named: ELIQUIS, FREESTYLE LIBRE 3, VRAYLAR, BREZTRI, AIRSUPRA, TRELEGY ELLIPTA, QULIPTA, REXULTI.
Industry payments across RI — which companies pay providers there.
